The use of viral vectors for gene delivery into mammalian cells provides a new approach in the treatment of many human diseases. The first viral vector approved for human clinical trials was murine leukemia virus (MLV), which remains the most commonly used vector in clinical trials to date. However, the application of MLV vectors is limited since MLV requires cells to be actively dividing in order for transduction and therefore gene delivery to occur. This limitation precludes the use of MLV for delivering genes to the adult CNS, where very little cell division is occurring. However, we speculated that this inherent limitation of MLV may be overcome by utilizing the known mitogenic effect of
Introduction
Of the viral vector systems currently being evaluated for clinical use, more than half of all approved clinical protocols utilize retroviral vectors. 1, 2 In particular, the retrovirus-based vector, murine leukemia virus (MLV), has been the most commonly used vector in clinical trials for both genetic and acquired diseases 3 due in part to its very simple genome, consisting of little more than the genes essential for replication. 4 Moreover, the associated risks with gene transfer are minimal since, in production of the vector, the viral genes are removed or altered so that viral replication cannot occur within the host cell. 3 In addition, MLV-based vectors can integrate their genetic material into the host cell genome, thereby increasing the likelihood of long-term transgene expression. 4, 5 Though MLV has been used extensively in research and clinical protocols, this specific group of retroviral vectors is limited in their scope of application because they can only transduce dividing cells. [5] [6] [7] This has been of particular concern when assessing the potential use of MLV in transferring genes to cells of the adult brain since these cells either do not divide, as with neurons, or are slow to divide, as with glial cells. For this reason, MLV has not been seriously considered as a potential vehicle for gene transfer in the treatment of neurological disorders. 8, 9 Presently, there is no description of a vector growth factors on cells of the CNS. Specifically, an in vivo application of growth factor to the adult brain, if able to induce cell division, could enhance MLV-based gene transfer to the adult brain. We now show that an exogenous application of basic fibroblast growth factor induces cell division in vivo. Under these conditions, where cells of the adult brain are stimulated to divide, MLV-based gene transfer is significantly enhanced. This novel approach precludes any vector modifications and provides a simple and effective way of delivering genes to cells of the adult brain utilizing MLVbased retroviral vectors. Gene Therapy (2000) 7, 1103-1111.
modification that allows MLV-based vectors to deliver genes effectively to cells of the adult brain, where minimal cell division is occurring. The use of MLV-based vectors for effectively delivering genes to the CNS may nevertheless be possible by exploiting the well-known mitogenic effects of growth factors on cells of the adult brain. For example, it has been demonstrated that growth factors induce cultured neuronal progenitor cells and glial cells to divide and that this mitogenic effect is cell type specific. [10] [11] [12] [13] Furthermore, retroviral gene transfer to the adult liver can be enhanced if the normally quiescent cells of this organ are first stimulated to divide by injury or growth factor administration. [14] [15] [16] Taken together, these findings support our hypothesis that an exogenous application of growth factor to the adult brain should stimulate cell division and in turn, enhance MLV-based gene transfer.
Preliminary studies by this group have shown that cells in the adult brain can be stimulated to divide upon an in vivo application of basic fibroblast growth factor, 17 a known CNS mitogen for both cultured glial cells and neuronal progenitor cells. 18, 19 This study was undertaken to determine the peak period, duration and cell specificity of growth factor-induced cell proliferation and to determine whether this cell division can enhance MLVbased gene transfer. We now show that an exogenous application of basic fibroblast growth factor (␤FGF) to the adult brain can have a profound effect on MLV-based retroviral gene transfer. 20 These results provide a rationale for re-evaluating the potential use of MLV-based vectors for gene therapy to the adult CNS. 
Results

␤FGF induces cell division in the adult brain
To investigate the potential of ␤FGF to stimulate cell division in the CNS, adult rats were given a single intracortical injection of ␤FGF, followed by injections of 5-bromodeoxyuridine (BrdU) at various times after the growth factor injection in order to determine the time-course of the cellular division. Since BrdU is a thymidine analog that is incorporated into dividing cells, those cells induced to divide could be identified with an antibody against BrdU. 21, 22 The normal cellular response of the adult CNS to physical injury is characterized by the reactivity of astrocytes around the injection site, the activation of microglia and a limited proliferation of cells. 23, 24 This characteristic response is also seen when placing a needle into the adult brain and delivering saline or ␤FGF ( Figure  1a-d) . However, beyond this expected response to injury the delivery of ␤FGF greatly enhanced cell division. By quantifying the number of dividing cells present in brains given a ␤FGF injection versus saline alone, the proliferative effect of ␤FGF was found to be higher than that of saline ( Figure 2 ) at all time-points studied throughout the examined period (4 h, 2 days, 4 days, and 7 days after injection). Moreover, the mitogenic effect of ␤FGF was found to be most pronounced at 48 h after injection, with significantly more cells dividing than at any other timepoint tested (P Ͻ 0.05). At this peak period of cell division, it was found that the number of cells dividing after a ␤FGF injection was seven times higher than the cell division created by an injection of saline (154 679 ± 16 858 versus 21 573 ± 9663; P Ͻ 0.05). This clearly suggests a growth factor-induced proliferative effect in the adult brain. Mitogenic effects of ␤FGF targets astrocytes and microglia The identity of cell types proliferating as a result of the ␤FGF injection was determined by utilizing a double labeling technique ( Figure 3 ). In order to identify the proliferating cell types, rats were given a single intracortical injection of ␤FGF or saline, followed 48 h later, by an intraperitoneal injection of 3 H-thymidine. Like BrdU, 3 Hthymidine is incorporated into dividing cells but is visualized using autoradiography. 25 This method was utilized for identifying dividing cell in place of BrdU staining because it was found that this method was more compatible with the immunohistochemical procedures used to identify cell types. Furthermore, others have shown that both methods for identifying dividing cells label the same population of cells. 21 Coronal brain sections throughout the injection sites of these animals were stained with antibodies specific to glial fibrillary acidic protein (GFAP), a marker specific to mature astrocytes, 26 Vimentin, a marker specific for immature astrocytes, 27 ED-1, a marker specific for activated microglia and macrophages 28 or NeuN, a marker specific to neurons. 29 Sections were then processed for autoradiography. A significant population of cells made to divide after a single intracortical injection of ␤FGF could be identified as astrocytes (Table 1) by their staining for either GFAP or Vimentin (24.4 and 35.4%, respectively). An injection of saline, on the other hand, induced 15% of GFAP-positive cells to divide and 23.8% of Vimentin-positive cells to divide. In both saline and ␤FGF groups, 23.2% and 18.6% of the total dividing cells labeled positive for ED-1 respectively. Additionally, it was found that in the ␤FGF group, 1.9% of the dividing cells labeled positive for NeuN, a marker specific to neurons. Gene Therapy ␤FGF enhances MLV-based gene transfer to the adult brain To test whether growth factor-induced cell proliferation would improve MLV-based retroviral gene transfer, adult rats were given an intracortical injection of ␤FGF or saline as described above. Forty-eight hours later, the animals were injected with MLV vector carrying the LacZ marker gene in the same site as the growth factor or saline injections. By waiting 48 h from the time of growth factor injection before delivering the viral vector, it was hypothesized that retroviral gene transfer could be optimized by making the viral injection at the peak period of cell division. A second control group received a single injection of MLV-LacZ with no prior injection of growth factor or saline. All animals were allowed to survive for 3 days before being killed and sections stained for the expression of ␤-galactosidase, the encoded product of the LacZ gene. In the control groups it was found that the number of cells transduced by an injection of MLV-LacZ alone was very low, with a mean number of LacZ-positive cells being approximately 2960 ± 1806. Likewise, rats injected with MLV-LacZ 48 h after the control saline injection contained 6281 ± 1456 LacZ-positive cells. Conversely, a pre-treatment of ␤FGF to the adult brain, 48 h before MLV-LacZ injection, significantly enhanced retroviral gene transfer to cells of the adult brain ( Figure 4) . Specifically, the numbers of LacZ-positive cells in this experimental group was 24 720 ± 7819; P Ͻ 0.05 ( Figure  5 ). This was well above the number of transduced cells found in either control groups and clearly demonstrated that the application of growth factor to the adult brain has a profound effect on MLV-based retroviral gene transfer. To identify astrocytes transduced by MLV-based vectors in rat brains first injected with ␤FGF, a group of these experimental animals was allowed to survive 2 weeks after viral injection. Brain sections were then double-stained with an antibody to ␤-galactosidase and an antibody to GFAP. The majority of transduced cells showed astrocytic morphology and when double stained, expressed the glial fibrillary acidic protein, GFAP ( Figure  6 ). This information supports our previous finding that ␤FGF acts as a mitogen on astrocytes and that these dividing cells can subsequently by transduced by the MLV vector. 
Discussion
In this study, we tested whether an intracortical application of growth factor could act to stimulate cell division in the adult brain, where minimal cell division is occurring. We hypothesized that the presence of these dividing cells in the adult brain would provide the necessary environment, that of active cell division, required for MLV gene transfer. This would make it possible to transfer genes to cells of the CNS, in potentially significant numbers, using MLV-based vectors. We now show that MLV-mediated gene delivery to cells of the adult brain can be significantly enhanced with an exogenous application of growth factor before viral vector application. This novel gene therapy approach precludes any vector modifications, and provides a simple and efficient way of delivering genes to cells of the adult brain utilizing MLV-based retroviral vectors.
The use of growth factors to enhance MLV-based gene transfer to the adult CNS should allow researchers to reevaluate MLV for its potential therapeutic use in the CNS. Currently, the viral vector systems being used for gene transfer to the CNS are based on the adenovirus, adeno-associated virus, herpes simplex virus and more recently, lentivirus. While each system holds promise, inherent limitations of each vector system currently pose problems which need to be overcome, if gene therapy for CNS disorders is to succeed. For example, although adenovirus can transduce both dividing and non-dividing cells in vivo, this virus elicits a strong host immune response, resulting in short-lived transgene expression. [30] [31] [32] Likewise, adeno-associated virus can transduce dividing and non-dividing cells, however, the transduction efficiency in some cells is very low and requires high numbers of viral particles per cell to be achieved. 33 Moreover, the lack of efficient packaging cells makes the production of this virus labor intensive. 34, 35 The herpes simplex virus can also transduce both dividing and nondividing cells, however, during latency, expression of the HSV genome is transcriptionally silent, with only the latency-associated transcripts (LATs) produced. 36, 37 This may result in the inactivation of the transgene not under LAT control. However, ongoing research in this area is promising, with longer transgene expression and less cytotoxicity being reported. 38 The retroviral vector systems based on the human immunodeficiency virus (HIV) or similar lentiviruses, which are currently being developed, are able to transduce both dividing and nondividing cells, [39] [40] [41] and like MLV, can integrate into the host cell genome. 4, 5 These lentiviral vectors are undergoing continued improvement to increase titre and eliminate the possibilites of generating replication competent lentiviruses. [42] [43] [44] [45] [46] Therefore, MLV vectors already in use have immediate clinical utility.
Since many CNS disorders are characterized by the destruction of populations of neurons or their biochemical products, the cells of the adult brain that are normally targeted for gene delivery have primarily been neurons. Nevertheless, gene delivery to other cells within an affected area of the brain may be sufficient to treat some CNS disorders. 47 In this current study, for example, we have found that one cell type made to divide by ␤FGF application was astrocytes. Since MLV requires active cell division for transduction and in this study, astrocytes were found to be the predominant cell type dividing, astrocytes are likely to be the predominant cell type susceptible to gene transfer. It should also be noted that the VSV-G envelope on our virus interacts with lipids in the plasma membrane and therefore enables this virus to theoretically transduce all cell types. 48 Nevertheless, even when using this envelope, MLV can only transduce cells that are actively dividing. This would preclude the transduction of neurons in the CNS since these cells are postmitotic. However, we would postulate that the absence of transduced neurons would not diminish the usefulness of this approach in treating neurologic diseases but may, in fact, be advantageous in some therapeutic strategies. For example, the transduction of astrocytes already integrated into the tissue can act as a 'biological mini-pump' releasing neurotransmitter or neurotrophic factors locally. 8, 49 This may have an advantage over viral vector systems targeting neurons, which can deliver transgene products in a retrograde or anterograde manner to sites far removed from the target area. The transport and release of gene products far removed from their site of action could undermine their usefulness, as well as have detrimental effects on normal brain function.
As stated above, the primary cell types affected by an in vivo application of ␤FGF were astrocytes. Since it is possible for GFAP and Vimentin to be co-expressed in some astrocytes, 50 we were unable, in this study, accurately to determine the total number of astrocytes induced to divide after a growth factor injection. However, assuming GFAP and Vimentin labeled distinct Gene Therapy populations of astrocytes, the total percentage of dividing astrocytes could be as high as 59%. If, however, every astrocyte which was made to divide was expressing both GFAP and Vimentin, then the total percentage of dividing astrocytes would be 35%. In either condition, the predominant cell type induced to divide by ␤FGF injection was astrocytes, and to a lesser extent, microglia. Further, it should be noted that the results shown in Table 1 imply that there is a population of unidentified dividing cell types. Specifically, after an injection of ␤FGF, 19.7% of the cells are unidentified and after an injection of saline, 37.8% of the cells are unidentified. These cell types could be either oligodendrocytes or a progenitor cell population which were not identified with any of the cell markers used in this study. In any case, this study provides clear evidence that a single intracortical injection of ␤FGF induces the proliferation of both astrocytes and, to a lesser extent, microglia in the adult CNS. Although our results indicate that the mitogenic effect of ␤FGF acts roughly comparable on astrocytes and microglia, this may merely be the consequence of the time period when dividing cells were identified. Specifically, we identified and quantified the cell types made to proliferate in animals at only one time-point (48 h post growth factor injection). Since it has been shown that the peak period of microglial proliferation following a minor cortical stab wound is approximately 48 h after the injury, 24 it is possible that the number of microglial cells made to divide, and therefore counted, is disproportionately higher than what one would see in other time periods after growth factor injection. Similarly, it has been shown that the proliferation of astrocytes following a minor cortical stab wound is 3-4 days after injury. 24 Based on this information, one might expect to have seen more dividing astrocytes if we had counted the cells at 3-4 days after injection.
Since ␤FGF, as well as other growth factors, have been shown to have a cell type-specific mitogenic effect, the methodology described in this paper may allow one to transduce specific cell types selectively in the CNS. For example, ␤FGF has been shown in vitro to have a potent effect on the proliferation of astrocytes 10, 51 and in vivo on microglia 52 as well as the survival of CNS neurons. 53 Epidermal growth factor has been shown in vitro to be a mitogen to both glial precursor cells and neuroepithelial cells, 54, 55 whereas platelet-derived growth factor stimulated the proliferation in vitro of oligodendrocyte/type 2 astrocyte progenitor cells. 12, 13 Induction of cell specific division in vivo would allow one to target MLV-based gene transfer, thereby tailoring a treatment for a specific neurodegenerative disease. In the treatment of Parkinson's disease, for example, the diminished levels of dopamine neurotransmitter within the basal ganglia could be augmented by astrocytes within the putamen transduced to express dopamine. 56 By selectively targeting these astrocytes, dopamine would be produced locally and released only at its site of action.
Similarly, other growth factors could be used to target oligodendrocytes or their progenitors so as to effect the production or maintenance of the myelin sheath. This could have potential application in the treatment of demyelinating diseases. To this end, we have begun investigating the mitogenic effect of a variety of growth factors introduced into the adult brain as well as assessing their cell type-specific action. 17 Furthermore, higher numbers of transduced cells may be achieved by a variety of methods. For example, one could use a higher titre vector or by varying the application of growth factor and virus to include multiple injections, thereby covering a larger area. Another possible way to increase the total numbers of cells transduced is by optimizing the dosage of growth factor or by giving a cocktail of growth factors using an osmotic pump. Nevertheless, some diseases may require only a small number of cells to effect behavioral changes. For example, the first symptoms of Parkinson's disease appear only when 80% of the dopaminergic innervation into the striatum have degenerated. 57 Therefore, it is possible that a relatively small number of astrocytes transduced to express tyrosine hyroxylase in the striatum may be sufficient to improve symptoms.
The new methodology described in this paper allows us to re-explore the potential use of MLV-based retroviral vectors for gene therapy to the adult CNS. The range of cell types transduced by MLV is no longer restricted to those cells that are normally dividing in the adult brain but can include those cells made to divide by growth factors. The inherent characteristics of MLV-based viral vector to integrate in the host genome and elicit little immune response 34 should then enable gene expression to persist in these cells. Therefore, this new approach of gene delivery to the adult CNS using MLV should broaden this vector's application to include the neurodegenerative diseases.
Material and methods
Surgical procedure and viral vector injection
To assess the mitogenic effect of an in vivo application of ␤FGF, adult Wistar rats (n = 24) were anaesthetised (0.6 ml per kg of body weight of xylazine (20 mg/ml) and ketamine (100 mg/ml)), placed in a stereotactic apparatus and given a unilateral intracortical injection of either ␤FGF (experimental) or saline (control) using a Hamilton syringe 3 mm posterior and 3 mm lateral to bregma and to a depth of 1.00 mm from the surface of the brain. Using this stereotactic procedure allowed us to produce a consistent and precise injection in both our control and experimental animals, thereby controlling for the variability in numbers of cells made to divide due to injectionrelated damage alone. Additionally, the length of the injection track for each animal was subsequently verified on a cresyl violet stained section.
A single 8 l injection of 100 ng/ml of ␤FGF-human recombinant (Promega, Madison, WI, USA) or saline was made over 8 min at a rate of 1 l/min. It should be noted that ␤FGF was dissolved in saline and heparan sulfate added at 10 g/ml, a factor required for binding of ␤FGF to its high affinity receptor. 58, 59 At various times after injection (4 h, 2 days, 4 days or 7 days), animals from each experimental or control groups were intraperitoneally (i.p.) injected with 5-bromodeoxyuridine (BrdU) every 60 min throughout a 4-h period. BrdU is a thymidine analog, which becomes incorporated into dividing cells. 21, 22 Therefore, cells induced to divide were identified with an antibody against BrdU. Forty-eight hours later, these animals were anaesthetised, perfused with phosphate buffer saline (PBS) and brains dissected, frozen and cut coronally at 10 m with a cryostat so as to include 1.5 mm rostral and caudal to the injection site. Every fifth section throughout the injection site was collected on slides, fixed and stained with either cresyl violet, a cell specific stain or an antibody to BrdU. The number of dividing cells present in these BrdU-stained sections was counted (see Quantification below) and this number, which was derived from a one in five series (20% of the lesion area), was then used to estimate the total number of dividing cells present throughout the injection site for each animal.
To determine the identity of the dividing cells, animals (n = 12) were injected intracortically with ␤FGF or saline (as described above) followed by an i.p. injection of H -thymidine at 5.0 Ci/g body weight, 48 h after growth factor injection. These 3 H-thymidine injections were given every 60 min for 2 h. Like BrdU, 3 H-thymidine is incorporated into dividing cells but is visualised using autoradiography. 25 Again, 3 H-thymidine was used in place of BrdU to label the dividing cells because we found that this method was more compatible with the immunohistochemical procedures used to identify cell types. Forty-eight hours later, the animals were killed and perfused with PBS. The brains were dissected out, frozen and cut at 10 m on a cryostat and immunostained for cell-specific antigens and processed for autoradiography. An additional group of five animals were left to survive 12 days after 3 H-thymidine injection. These animals were used to identify microglia and macrophages made to divide by growth factor application since the ED-1 staining of animals left to survive only 48 h after 3 H-thymidine injection was obscured by blood along the injection site.
To test whether growth factor-induced cell proliferation would improve MLV-based retroviral vector gene transfer, adult rats (n = 12) were given an intracortical injection of ␤FGF (experimental) or saline (control) as described above and then injected 48 h later, in the same site, with MLV vectors carrying the LacZ gene (see below). An additional control group received the MLV injection with no prior injection of saline or growth factor. The titre of the viral vector was 1 × 10 7 transforming units (TU)/ml as measured on 293T cells and a total of 8 l of this solution (a total of 80 000 TUs) was injected at a rate of 1 l/min. Animals were allowed to survive for 3 days before being killed, brains dissected and cut as described above. Section were then stained for the presence of LacZ.
Cell type identification using immunohistochemistry and autoradiography To quantify dividing cells, an antibody to BrdU was used. Specifically, sections through the injection site were collected on to slides, fixed in ice-cold acetone, washed and incubated in a formamide solution (95% formamide, 1.5% SSC in water) for 35 min at 70°C. Sections were then washed in ice-cold PBS and incubated in BrdU antibody (mouse monoclonal 1:20, Dako, Carpinteria, CA, USA) in PBS containing 4% normal goat serum (NGS) and 0.5% BSA for 1 h at room temperature. Sections were washed again and incubated in peroxidase-conjugated antimouse secondary antibody (1:200, Dako) in PBS containing 4% NGS. Histochemical detection of peroxidase activity was performed using diaminobenzidine (DAB) and hydrogen peroxide.
To determine the specific identify of the dividing cells, consecutive 10 m sections from each brain were stained using antibodies to GFAP, a marker specific to astrocytes, 26 Vimentin, a marker for immature astrocytes, 27 NeuN, a marker specific to neurons, 29 and ED-1, a marker specific to microglia and macrophages. 28 Specifically, section were fixed in 4% paraformaldehyde (for ED-1, ethanol was used as a fix) in PBS, washed and incubated overnight in the primary antibody (anti-rabbit GFAP at 1:1000, Dako; anti-mouse Vimentin at 1:1000, Sigma, St Louis, MO, USA; anti-mouse NeuN at 1:100, gift from Charles Buck (Dept of Physiology, Emory University, Atlanta, GA, USA); anti-rat ED-1 at 1:1000, Serotec, Raleigh, NC, USA) in PBS with 4% NGS and 1% triton. Sections were washed in PBS and incubated in antimouse, anti-rat or anti-rabbit, peroxidase-conjugated secondary antibodies (1:200) . Histochemical detection of peroxidase activity was performed using DAB and hydrogen peroxide. Sections were then left to dry and then dipped in photographic emulsion (Kodak NBT2 obtained via VWR, Bridgeport, NJ, USA) and left to develop for 4 weeks at 4°C, in the dark. Sections were developed using Kodak D-19 developer for 4 min at 15°C, rinsed in water, fixed for 5 min, washed in water, air dried and coverslipped.
To determine the number of cells transduced by MLVLacZ viral vectors in experimental (␤FGF-injected) or control (saline-injected) animals, sections throughout the injection site were stained for the expression of ␤-galactosidase. Specifically, rats were anaesthetised 2 days after viral injection and perfused with PBS followed by 4% paraformaldehyde/0.1% gluteraldehyde fixative. The brains were removed, immersed in the same fixative for 3 h at 4°C, then overnight in PBS with 2 mm MgCl 2 and 30% sucrose at 4°C. The brains were cut coronally at 10 m with a cryostat, the sections collected on slides and stained for X-gal histochemistry. Specifically, sections were placed in the following solution: 3.5 ml PBS, 0.5 ml of 50 mm stock potassium ferricyanide, 0.5 ml of 50 mm stock potassium ferrocyanide, 0.2 ml of 50 mm stock MgCl 2 , 50 l of 1% solution sodium deoxycholate and 100 l 1% solution of Igepal CA 620 (pH 7.2) (ICN Biomedicals, Aurora, OH, USA). Finally, 5 mg of X-gal was mixed with 125 l of DMSO and added to the above solution. Slides were then immersed in this solution for 3 h at 37°C, washed with PBS, then dH 2 O and left to air dry.
Astrocytes transduced by the MLV-LacZ viral vectors were identified using a double-staining procedure. Briefly, slides were washed twice with PBS before pooling the primary antibodies, rabbit anti-␤-galactosidase (1:1000; Cortex, Irvine, CA, USA) and guinea pig anti-GFAP (1:250; Advanced Immunochemicals, Longbeach, CA, USA) in 10% normal horse serum and 0.3% triton in PBS. Slides were left at 4°C for 72 h after which they were washed three times in PBS. The secondary antibodies, FITC-conjugated anti-rabbit IgG (Jackson Immunochemicals, West Grove, PA, USA) and RITC-conjugated antiguinea pig IgG (Jackson Immunochemicals) were pooled at 1:200 each in PBS with 10% normal horse serum and incubated on the sections for 2 h in the dark. Slides were then washed 3× in PBS, 2× in distilled water, coverslipped and analyzed with an Olympus BX60 microscope (Melville, NY, USA).
Quantification
To determine the total number of BrdU or Lac-Z-positive cells in the brains of rats, every fifth section throughout Gene Therapy the areal extent of the injection site was examined at 20× with a Nikon microscope (Melville, NY, USA) and projected via a video camera hookup to a colour monitor. Individual labeled cells were counted for each section and this information was stored for statistical evaluation using Neurolucida software (MicroBrightfield, Colchester, VT, USA). The statistical significance of the cell counts was determined using SSPS statistical program software to perform a one-way analysis of variance with a post hoc test (Bonferroni) to determine significance between groups.
Double-labeled cells were quantified by microscopic examination of the sections. Specifically, for each cellspecific stain, a section taken through the lesion was transferred to a microscope interface with a computerassisted image analysis system (Imaging Research, St Catherine's, Ontario, Canada). The injection area was enlarged to a magnification of 20× to 40× and the total number of dividing cells was counted. The identity of these thymidine-positive cells was determined by immunostaining. The percentage of each dividing cell type was then determined with this information. A positively labeled 3 H-thymidine cell was defined as a group of four or more silver grains over the nucleus of the cell, assuming background grain counts in an area the approximate size of the nucleus are one or less. 60 Vector construction MLV-LacZ was made as described previously. 61 Briefly, vector stocks were generated by calcium-phosphate transfection of human kidney 293T cells and plated on 10 cm dishes with 16 g of vector plasmid (pHIT111), 16 g of gag-pol plasmid (pHIT60) and 8 g of pRV67 plasmid VSV-G envelope. 62 Forty-eight hours after transfection, supernatants were filtered (0.45 g), divided into aliquots and stored at −70°C. Concentrated vector preparations were made by ultracentrifugation at 20 000 r.p.m. (SW40ti rotor) for 90 min at 4°C. The virus was resuspended in PBS for 3-4 h, divided into aliquots and stored at −70°C. Transduction was carried out in the presence of polybrene (8 g/ml).
